9 Meters Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017 - 2014
Net Income	-43.77	-36.78	-61.5	-27.05	-24.16	Upgrade
Depreciation & Amortization	0.01	0.01	0.02	0.02	0.02	Upgrade
Share-Based Compensation	3.94	2.41	4.72	2.87	3.81	Upgrade
Other Operating Activities	2.58	4.88	37.35	6.19	5.17	Upgrade
Operating Cash Flow	-37.24	-29.48	-19.41	-17.97	-15.17	Upgrade
Capital Expenditures	-0	-0.01	-0	-0.01	-0.01	Upgrade
Acquisitions	0	-2.49	-3.18	0	0	Upgrade
Change in Investments	0	0.08	0	0	0	Upgrade
Investing Cash Flow	-0	-2.43	-3.19	-0.01	-0.01	Upgrade
Share Issuance / Repurchase	0	44.01	39.68	20.74	19.24	Upgrade
Debt Issued / Paid	19.91	-0.06	0.02	-2.85	3.02	Upgrade
Other Financing Activities	-	-2.9	16.16	-1.05	-1.71	Upgrade
Financing Cash Flow	19.91	41.05	55.86	16.84	20.56	Upgrade
Net Cash Flow	-17.33	9.14	33.26	-1.14	5.37	Upgrade
Free Cash Flow	-37.25	-29.49	-19.41	-17.98	-15.18	Upgrade
Free Cash Flow Per Share	-2.88	-2.43	-3.67	-10.79	-12.26	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).